Rationale: Pulmonary hypertension (PH) associated with fibrotic idiopathic interstitial
pneumonia (IIP; idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia) confers …

Increasing bacterial burden in the lower airways of patients with idiopathic pulmonary
fibrosis confers an increased risk of disease progression and mortality. However, it remains …

There is growing evidence of the role of infection in the pathogenesis and progression of
idiopathic pulmonary fibrosis (IPF) [1–4]. Over a third of patients with IPF will be hospitalised, at …

Introduction The King’s Brief Interstitial Lung Disease (KBILD) is a 15-item validated health-related
quality of life (HRQOL) questionnaire. The method of scoring the KBILD has recently …

Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF), reduces annual forced vital capacity (FVC) decline in these patients by ∼50% …

Background and objective: The aim of the present study was to report the features of five
patients with concurrent histopathological features of pulmonary alveolar proteinosis (PAP) and …

Background Establishing whether patients are exposed to a ‘known cause’ is a key element
in both the diagnostic assessment and the subsequent management of hypersensitivity …

There is a well-known association between the connective tissue disorders (CTDs) and
lung disease. In addition to interstitial lung disease, the CTDs may affect the air spaces and …

Attrition of TL is associated with the development and progression of pulmonary fibrosis. TL
length has been shown to be reduced in individuals with SSC vs healthy controls. ILD …

Introduction: Routine and international comparison of clinical outcomes based on a standardized
outcome indicator set in patients with pulmonary sarcoidosis is lacking. Objectives: To …